NASDAQ : TWST

Twist Bioscience Corporation

$115.01 USD

$15.56 (15.65%)

Volume
3.28M
Average Volume
1.71M
Market Capitalization
$7.16B
P/E Ratio
-51.81
Dividend Yield
0.00%
Price Target
$107.00
Year High
$115.56
Year Low
$23.30
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.67
Company Overview

NASDAQ

Emily Marine Leproust

Medical - Diagnostics & Research

Healthcare

TWST

979

US

USD

https://www.twistbioscience.com

800 719 0671

90184D100

0001581280

Liquidity Metrics

0.21

2.67

2.38

0.98

0.00

Sales & Valuation

$376.57M

16.59

16.10

-76.91

-1.49

Profitability

-$1.3

-$77.67M

-31.66%

-31.46%

-29.89%

-20.33%

P/E Metrics

-51.81

0.79

0.79

Analyst Price Target & Rating

$107.00

$120.00

$89.00

Sell

2/5

14 Analysts

7.49%

Financial Health Scores

13.76

2/9

$201.04M

$672.44M

$226.7M

-$133.18M

Key Metrics (TTM)

$6.17B

14.29

-57.23

2.67

-29.89%

-24.57%

-2.20%

-1.50%

87 days

Company Executives
Name Title
Michael Fero Chief Information Officer
Emily Marine Leproust Co-Founder, Board Chair & Chief Executive Officer
Patrick John Finn President & Chief Operating Officer
Adam Laponis Chief Financial Officer
Dennis Cho Chief Legal Officer & Corporate Secretary
Robert F. Werner Vice President & Chief Accounting Officer
Siyuan Chen Chief Technology Officer
Nicole Moreno Senior Vice President of Sales & Support
Paula Green Senior Vice President of Human Resources
Colby Souders Chief Scientific Officer
Poll Results

No votes yet today — be the first to share your view!

About Twist Bioscience Corporation (NASDAQ:TWST) Stock

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centoge ... ne N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

2026-08-05 10:08:02

Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve.

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

2026-08-05 00:00:00

Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten pu

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

2026-08-04 23:45:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissio.

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

2026-08-04 16:01:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2026-08-04 08:00:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (“RSUs”) will be granted to 24 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and Res.

First Trust Advisors LP Acquires New Holdings in Twist Bioscience Corporation $TWST

2026-08-04 04:05:30

First Trust Advisors LP acquired a new position in Twist Bioscience Corporation (NASDAQ: TWST) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 104,650 shares of the company's stock, valued at approximately $4,973,000. First Trust Advisors LP owned

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

2026-08-03 14:39:54

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

Twist Bioscience Sees AI Drug Discovery Pipeline Expand

2026-08-03 12:13:44

Twist Bioscience Corporation (NASDAQ:TWST) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance.

Frequently Asked Questions

What is the current Twist Bioscience Corporation (TWST) stock price?

Twist Bioscience Corporation(NASDAQ:TWST) stock price is $115.01 in the last trading session. During the trading session, TWST stock reached the peak price of $115.56 while $23.3 was the lowest point it dropped to. The percentage change in TWST stock occurred in the recent session was 15.65% while the dollar amount for the price change in TWST stock was $15.56.

TWST's industry and sector of operation?

The NASDAQ listed TWST is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of TWST?

Michael Fero | Chief Information Officer
Emily Marine Leproust | Co-Founder, Board Chair & Chief Executive Officer
Patrick John Finn | President & Chief Operating Officer
Adam Laponis | Chief Financial Officer
Dennis Cho | Chief Legal Officer & Corporate Secretary

How many employees does TWST have?

Number of TWST employees currently stands at 979. TWST operates from 681 Gateway Boulevard, South San Francisco, CA 94080, US.

Link for TWST official website?

Official Website of TWST is: https://www.twistbioscience.com

How do I contact TWST?

TWST could be contacted at phone #800 719 0671 and can also be accessed through its website. TWST operates from 681 Gateway Boulevard, South San Francisco, CA 94080, US.

How many shares of TWST are traded daily?

The average number of TWST shares traded daily for last 3 months was 1.71M.

What is the market cap of TWST currently?

The market value of TWST currently stands at $7.16B with its latest stock price at $115.01